Posted by Michael Wonder on 05 Nov 2020
Lynparza approved in the EU for the treatment of BRCA mutated metastatic castration-resistant prostate cancer
5 November 2020 - Only PARP inhibitor to improve overall survival versus new hormonal agent treatments in BRCA mutated metastatic castration-resistant prostate cancer
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union for patients with metastatic castration-resistant prostate cancer with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations, a sub-population of homologous recombination repair gene mutations.
